Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 11/20 | 0.50 |
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634028 | 0.93 | TFPI (0.53) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL31369291 | 0.85 | KISS1R (0.61) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL13634040 | 0.83 | TFPI (0.56) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL31369292 | 0.83 | KISS1R (0.57) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL8894949 | 0.80 | BACE1 (0.61) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL29520890 | 0.79 | BACE1 (0.57) | BACE1BACE2KISS1R | |
| SCHEMBL29611494 | 0.78 | BACE1 (0.58) | TFPIBACE1BACE2IL23R | |
| SCHEMBL13634029 | 0.78 | BACE1 (0.50) | TFPIBACE1BACE2 | |
| SCHEMBL30974094 | 0.78 | KISS1R (0.53) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL30974431 | 0.77 | KISS1R (0.53) | TFPIBACE1BACE2KISS1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191123-A1 | NOVEL IMAGING AGENTS | MMP1, CD68, KIT | TFPI 183/4885BACE1 4028/4885BACE2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.